Nateglinide

American Journal of Health-System Pharmacy

Volumn 58, Issue 13, 2001, Pages 1200-1205

  Halas, C J ^a   Kay, L ^a  

^a University HealthSystem Consortium   (United States)

Author keywords

Antidiabetic agents; Combined therapy; Diabetes mellitus; Dosage; Drug interactions; Mechanism of action; Metformin; Nateglinide; Pharmacoeconomics; Pharmacokinetics; Toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CYTOCHROME P450; ERYTHROMYCIN; FLUCONAZOLE; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; POTASSIUM CHANNEL; POTASSIUM ION; RIFAMPICIN; SULFONYLUREA DERIVATIVE;

ARTICLE; CALCIUM TRANSPORT; CLINICAL TRIAL; DIARRHEA; DIET; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; EXERCISE; HUMAN; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; VERTIGO;

EID: 0035396205     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.13.1200     Document Type: Article

References (21)

1. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
2. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus
3. Diagnosis and classifications
4. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
5. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166
6. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin
7. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects
8. Nateglinide (A-4166), a new insulinotrophic agent, controls prandial hyperglycemia in type 2 diabetic patients
9. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus
10. Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes
11. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose spikes in type 2 diabetes
12. Nateglinide added to metformin offers safe and effective treatment for type 2 diabetes
13. Nateglinide improves glycemic control alone and in combination with troglitazone in patients with type 2 diabetes
14. Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects
15. Reduced postprandial hyperglycemia by A-4166 compared to voglibose in NIDDM subjects in Japan
16. Nateglinide (A-4166) controls glycemia in diet-treated type 2 diabetic patients
17. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis
18. Providing quality diabetes care in a cost-constrained environment
19. Insulin secretagogues: Sulfonylureas and repaglinide